Treprostinil Injection (Remodulin®, generic)

Treprostinil injection (Remodulin® and generic) is covered for WHO Group I pulmonary arterial hypertension (including transition from epoprostenol) and compendial off‑label use for CTEPH, but only as continuous subcutaneous or intravenous infusion (preferably subcutaneous); other uses/routes are not authorized. Key requirements include WHO Group I PAH confirmed by right‑heart catheterization for initial/renewal, documented WHO functional class III/IV (or class II with prior trial of specified oral/inhaled/parenteral therapy), specified idiopathic PAH vasodilator/CCB criteria, prescribing/consultation by a pulmonologist or cardiologist, a dosing/administration plan, 12‑month approvals (with up to a 30‑day temporary supply if documentation is incomplete).

"Chronic thromboembolic pulmonary hypertension (CTEPH) (Approved Off-label Compendial Use)."

Sign up to see full coverage criteria, indications, and limitations.